Navigation Links
Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
Date:10/24/2013

nd the costs of integrating SARcode Biosciences Inc. ("SARcode") and Premacure AB ("Premacure"). In Q3 2012 integration and acquisition costs ($2.7 million) primarily related to the acquisition of FerroKin Biosciences, Inc. ("FerroKin") and the integration of Advanced BioHealing Inc. ("ABH").

Interest expense

For the three months to September 30, 2013 Shire incurred interest expense of $9.0 million (Q3 2012: $9.2 million), which principally relates to the coupon on Shire's $1,100 million 2.75% convertible bonds due May 2014.

Taxation


The effective rate of tax on Non GAAP income in Q3 2013 was 19% (Q3 2012: 18%), and on a US GAAP basis the effective rate of tax was 16% (Q3 2012: 15%).

The effective rate of tax in Q3 2013 on both a Non GAAP and a US GAAP basis is higher than the same period in 2012 due primarily to adverse changes in profit mix and changes in provisions for uncertain tax positions, partially offset by changes in estimates of the amount of certain tax liabilities following the finalisation of various tax returns.

FINANCIAL INFORMATION

TABLE OF CONTENTS

Page Unaudited US GAAP Consolidated Balance Sheets 11 Unaudited US GAAP Consolidated Statements of Income 12 Unaudited US GAAP Consolidated Statements of Cash Flows 14 Selected Notes to the Unaudited US GAAP Financial Statements (1) Earnings per share 16 (2) Analysis of revenues 17 Non GAAP reconciliation 19

Unaudited US GAAP financial position as of September 30, 2013
Consolidated Balance Sheets

September 30, December 31, 2013 2012 $M $M ASSETS Current assets: Cash and cash equivalents 1,686.1 1,482.2 Restricted cash 16.6 17.1 Accounts receivable, net 1,037.8 824.2 Inventories 480.5 436.9 Deferred tax asset 210.6 229.9 Prepaid expenses and other current assets 282.3 221.8 Total current assets 3,713.9 3,212.1 Non-current assets: Investments 36.7 38.7 Property, plant and equipment ("PP&E"), net 965.1 955.
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
11. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... March 25, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... a result of recent discussions with certain shareholders representing ... the Company, after dealing with certain matters including the ... of shareholders on March 26, 2015 (the "Meeting") it ... of directors will take place when the Meeting reconvenes. ...
(Date:3/25/2015)... , March 25, 2015  S&P Capital ... Factual Stock Report coverage on Abattis Bioceuticals ... ATTBF; CSE: ATT): is a specialty biotechnology company ... cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, ... in North America . The ...
(Date:3/25/2015)... SHANGHAI , CAMBRIDGE, Mass. and ... -- WuXi NextCODE, which provides comprehensive capabilities for using the ... deCODE genetics on their publication of the largest studies of ... published today online in Nature Genetics ... date of sequence variation, authored by a team of deCODE ...
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... 2012  Patients with gynecologic cancer have new hope in ... Center at University Hospitals (UH) Case Medical Center.  A ... is among the first in the nation to launch ... treat ovarian, endometrial and select other cancers. ...
... N.J., Jan. 20, 2012  Insmed Incorporated (Nasdaq CM: ... U.S. Food and Drug Administration (FDA) has lifted ... amikacin for inhalation) in patients with non-tuberculous mycobacteria ... discussions with FDA regarding the clinical hold placed ...
... N.Y., Jan. 19, 2012  Netsmart, the leading provider ... organizations nationwide, today announced the launch of ... highlight the positive clinical and financial impacts provided ... (Logo: http://photos.prnewswire.com/prnh/20110620/NY22778LOGO ) In ...
Cached Biology Technology:UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients 2UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients 3Insmed Incorporated Provides Corporate Update 2Insmed Incorporated Provides Corporate Update 3EveryDayMatters.com Aims to Raise Awareness and Coordinate Care Between Mental and Physical Health 2EveryDayMatters.com Aims to Raise Awareness and Coordinate Care Between Mental and Physical Health 3
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/23/2015)... YORK , March 23, 2015   HOYOS ... property management company, today announced that the Company will ... for both enterprise and consumers at Connect:ID on March ... HOYOS Labs will highlight the IEEE Biometric ... TM ; and enterprise access control system. BOPS ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... that in which they exist naturally, proteins and multiprotein ... they exhibit when in the static form in which ... College of Medicine in a report in the current ... study using electron cryomicroscopy, Dr. Steven Ludtke, assistant professor ...
... place is not a Rudyard Kipling “Just So?story, but an ... results. For a chicken, it’s the difference between having feathers ... of Southern California and mathematicians at Oxford University in the ... To understand patterning on the molecular and the systems level, ...
... novel way of combating diseases related to the immune system, ... and arthritis. The study, funded by the Wellcome Trust, appears ... by the body to fight infection. Scientists previously identified two ... T cells", which attack infected cells, and "regulatory T cells", ...
Cached Biology News:Embryonic patterning makes the feathers fly 2T for two: Scientists show how immune system chooses best way to fight infection 2
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
Luminometers...
cDNA Size Fractionation Columns offer an efficient and convenient method for size-fractioning double-stranded cDNA....
Homo sapiens inhibin, beta B (activin AB beta polypeptide) Antigen: Recombinant Protein(142~254aa)...
Biology Products: